Gilead Sciences Inc (NASDAQ:GILD) Sentiment Falls to 0.8, Because

May 16, 2018 - By Cynthia Ashman

Gilead Sciences, Inc. (NASDAQ:GILD) Corporate Logo

“Big money” Positions

“Big money sentiment for Gilead Sciences Inc (NASDAQ:GILD) in 2017 Q4 decreased to 0.8, revealed SEC filings. That’s down -0.23, from 2017Q3’s 1.03. 515 active investment managers increased and started new holdings, while 640 sold and reduced their holdings in Gilead Sciences Inc so the sentiment dropped. These funds own 972.68 million shares, that’s up from 957.62 million shares in 2017Q3. Funds holding Gilead Sciences Inc in top 10 decreased from 68 to 40 for a decrease of 28. In total 95 funds closed positions, 545 reduced and 411 increased. Also 104 funds bought new Gilead Sciences Inc stakes.

Largest Gilead Sciences Inc Investors

As of 2017 Q4 Healthcare Value Capital Llc has 16.34% invested in Gilead Sciences Inc. Gilead Sciences Inc’s shareholder Krensavage Asset Management Llc owns 478,053 shares as of 2017 Q4. Underhill Investment Management Llc reported 204,700 shares. The Massachusetts-based fund Tekla Capital Management Llc have invested about 6.96% of the active investment manager’s stock portfolio in Gilead Sciences Inc. The Alabama-based fund Cabot holds 137,230 shares or 5.98% of their stocks portfolio.

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East.The company has $87.82 billion market cap. The companyÂ’s products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.25.69 is the P/E ratio. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B.

GILD is touching $67.54 during the last trading session, after increased 0.82%.Gilead Sciences, Inc. has volume of 4.26 million shares. Since May 16, 2017 GILD has risen 9.79% and is uptrending. The stock underperformed the S&P 500 by 1.76%.

On July, 25 is anticipated Gilead Sciences, Inc. (NASDAQ:GILD)’s earnings report, Faxor reports. Analysts forecast $1.43 EPS. That’s $1.08 down or 43.03 % from 2017’s earnings of $2.51. GILD’s profit could be $1.86B with 11.81 P/E in case $1.43 EPS is published. 4.38 % EPS growth is what Wall Street’s predicts after $1.37 reported EPS last quarter.

Opus Point Prtnrs Mngmt Ltd Llc reported 3,075 shs. Capwealth Advsrs Limited Liability reported 1.95% of its capital in Gilead Sciences, Inc. (NASDAQ:GILD). 387,131 were accumulated by Renaissance Gru Limited Liability Corporation. State Bank Hapoalim Bm reported 21,262 shs stake. Dynamic Ltd has 0.1% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 3,895 shs. Advisory Rech reported 3,036 shs stake. Virginia Retirement Et Al reported 0.19% of its capital in Gilead Sciences, Inc. (NASDAQ:GILD). Temasek Holding (Private) has 11.13M shs. Vantage Advisors Limited Co has invested 0.06% in Gilead Sciences, Inc. (NASDAQ:GILD). Tcw has invested 1.31% in Gilead Sciences, Inc. (NASDAQ:GILD). Moreover, Paradigm Ltd Liability Co has 0.16% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Florida-based Dreman Value Management L L C has invested 0.6% in Gilead Sciences, Inc. (NASDAQ:GILD). New Mexico Educational Retirement Board owns 125,476 shs. Private Ocean Llc, California-based fund reported 1,049 shs. 123,759 were accumulated by Fosun Intl Limited.

Gilead Sciences, Inc. had 22 selling transactions and 0 insider buys since January 2, 2018. This’s net activity of $44.80 million. The insider Cogan John Francis sold 5,833 shs worth $430,130. On Tuesday, January 16 Meyers James R had sold 100,000 shs worth $8.02M. Alton Gregg H sold $2.37 million worth of stock or 30,000 shs. Washington Robin L also sold $401,566 worth of Gilead Sciences, Inc. (NASDAQ:GILD) shs. On Monday, April 2 the insider MARTIN JOHN C sold $3.66M.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

Total analysts of 14 have positions in Gilead Sciences (NASDAQ:GILD) as follows: 8 rated it a “Buy”, 0 with “Sell” and 6 with “Hold”. The positive are 57%. Since November 30, 2017 according to StockzIntelligence Inc Gilead Sciences has 24 analyst reports. On Wednesday, February 7 the rating was maintained by RBC Capital Markets with “Buy”. On Wednesday, January 3 the rating was maintained by Credit Suisse with “Hold”. On Wednesday, May 2 the stock has “Buy” rating by RBC Capital Markets. In Thursday, February 22 report Leerink Swann maintained the stock with “Hold” rating. On Tuesday, January 2 the rating was maintained by BMO Capital Markets with “Hold”. In Friday, January 26 report Jefferies upgraded the stock to “Buy” rating. The stock rating was maintained by Mizuho with “Buy” on Monday, February 12. On Tuesday, January 30 the rating was upgraded by Citigroup to “Buy”. On Tuesday, January 16 the firm earned “Outperform” rating by Wells Fargo. On Wednesday, December 20 the firm earned “Neutral” rating by Credit Suisse.

For more Gilead Sciences, Inc. (NASDAQ:GILD) news brought out recently go to:,,, or The titles are as follows: “Gilead Sciences: Resist Sentiment, Stop Speculating And Invest” brought out on May 15, 2018, “Kite Pharma continues buildout for cell therapy manufacture” on May 15, 2018, “Analysts Show More Caution Toward Gilead’s Mystical Recovery” with a publish date: May 02, 2018, “Bellicum Pharmaceuticals: Will This CAR-TCR Innovator Deliver Robust Profits?” and the last “FDA OKs expanded use for Gilead’s Truvada” with publication date: May 15, 2018.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: